Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moderna COVID-19 Vaccine in Immunosuppressed Adults
NCT04806113Phase 3Completed
- Sponsor
- McGill University Health Centre
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by McGill University Health Centre. Primary endpoints: Frequency and grade of solicited local and systemic adverse events and Frequency and grade of any unsolicited adverse events. Started Mar 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04806113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806113.